Clinical Genomics, Bridgewater, NJ, has announced that its New Jersey laboratory, which meets the certification requirements of the Clinical Laboratory Improvement Amendments of 1988 and is accredited by the College of American Pathologists, is now licensed by the Florida Agency for Healthcare Administration to offer services for patients residing within the state of Florida.
Clinical Genomics is the sole provider of Colvera, a liquid biopsy ctDNA assay used to detect residual and recurrent disease in patients previously diagnosed with colorectal cancer.
Lawrence LaPointe, Clinical Genomics.
“This approval allows Florida doctors to offer Colvera to their patients in one of the largest US oncology markets,” says Lawrence LaPointe, president and chief executive of Clinical Genomics.
“We are pleased to make available our world-class liquid biopsy testing to colorectal cancer surgeons and medical oncologists for the nearly 10,000 patients in Florida who are treated for colorectal cancer each year,” says John P. Alsobrook II, PhD, DABCC, FACB, laboratory site director and vice president of operations for Clinical Genomics pathology.
